[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC

It is with great interest that we read the report of the SARAH trial by Valérie Vilgrain and colleagues, recently published The Lancet Oncology.1 This paper reports the results of a large randomised phase 3 study in patients with advanced hepatocellular carcinoma (HCC), who showed no benefit in terms of overall survival after receiving yttrium-90 (90Y)-loaded resin microsphere selective internal radiation therapy (SIRT), as compared with sorafenib in an intention-to-treat approach. We believe at least three major adjustable elements could have contributed to the negativity of the trial.

http://ift.tt/2E1vSjL